Patrys Ltd (ASX:PAB)’s inaugural non-executive chair John Read will retire from his role as chair and director of the company, effective from Wednesday, August 31, 2022. Michael Stork (non-executive director) will take on the interim chair role as the company searches for someone with the correct expertise to fill the position.
“It has been an absolute privilege to be part of the Patrys leadership team since the company’s listing on the ASX in 2007,” the outgoing chair said.
“I am particularly proud of our progress in advancing the deoxymab platform in preparation for its first in human clinical trial planned for the second half of calendar year 2023.
“I am indebted to my fellow directors and Patrys’ CEO, Dr James Campbell, for their wisdom, professionalism and dedication.
“With the successful conclusion of the PAT-DX1 engineering run, it is now wholly appropriate that Patrys appoints a new chair for its next chapter as it focuses on becoming a clinical stage therapeutic antibody company.”
Toward the clinical stage of therapeutics
John Read guided the development of Patrys’ deoxymab antibody technology platform while working closely with CEO Dr James Campbell to expand the portfolio of clinical applications and partnerships for Patrys’ deoxymab technology.
“John has made a sustained and significant contribution to Patrys since his appointment as chair in May 2007,” Patrys CEO Dr James Campbell said.
“Patrys has transformed considerably under John’s stewardship, and he leaves the company in a strong position and with a clear trajectory to becoming a clinical-stage company.
“On a personal front, I am very grateful for John’s knowledge, support, expertise, wise counsel and guidance over the years.
“On behalf of the board, I would like to extend my heartfelt thanks to John and wish him every success in his future endeavours.”